Compare MTEX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | ADVB |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.6M |
| IPO Year | 1998 | 2023 |
| Metric | MTEX | ADVB |
|---|---|---|
| Price | $9.02 | $3.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.7K | ★ 33.5K |
| Earning Date | 11-24-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3431.25 |
| EPS | 1.02 | ★ 5.33 |
| Revenue | ★ $108,038,000.00 | $127,637.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.31 | ★ $0.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.80 | $1.80 |
| 52 Week High | $9.97 | $113.80 |
| Indicator | MTEX | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 43.51 |
| Support Level | $6.26 | $1.80 |
| Resistance Level | $9.65 | $5.59 |
| Average True Range (ATR) | 0.58 | 0.48 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 86.21 | 57.08 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.